2,266 press releases in English indexed under biotech & pharma.
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course...
Beyond treatment intent, the complete clinical workflow will include tools for the physician, physicist, dosimetrist, therapist and nurse. It builds on collaboration with the University of Michigan and Cone Health, part of Risant Health. BOONE, N.C., Sept. 24, 2026 -- Fuse...
Support for vaccines is high — vaccination isn't. More than half of US adults did not try to get a flu, COVID-19, RSV, or pneumococcal vaccine in the past year, and many remain unsure which ones are recommended for them NFID launches National Respiratory Communications Initiative to help...
“AI is bringing greater speed and precision to vaccine adjuvant research, helping advance smarter formulations and next-generation vaccines.”
When COVID-19 emerged, scientists had a crucial advantage: Decades of prior research on coronaviruses meant they understood the virus’ key proteins well enough to design vaccines in record time. The next pandemic may not offer the same head start. To help improve the odds, NVIDIA has joined a coalition of global research organizations, including Google […]
NEW YORK, Sept. 24, 2026 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden.
BALA CYNWYD, Pa., Sept. 24, 2026 -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 -- Lakewood-Amedex...
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly...
Lupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms Lupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms